HCM HUTCHMED (China) Limited
Price Chart
Executive Summary
HUTCHMED announced positive Phase 3 results for sovleplenib in warm AIHA (wAIHA), showing a 66% durable response rate vs 15% for placebo (p<0.0001). The NDA for wAIHA has been accepted and granted priority review by China's NMPA, and a separate resubmitted NDA for ITP also received priority review. These developments significantly strengthen sovleplenib's regulatory and commercial prospects in two indications with high unmet need.
Actionable Insight
Traders should monitor NMPA approval decisions for sovleplenib in both wAIHA and ITP — priority review timelines typically 6 months, so decisions could come by late 2026 / early 2027. Positive outcomes would be major catalysts for HCM as a pure-play owner of a first-in-class Syk inhibitor. Near-term, watch for potential partnership or ex-China licensing deals given HUTCHMED retains global rights.
Key Facts
- Phase 3 ESLIM-02 study met primary endpoint: durable response rate 66% for sovleplenib vs 15% for placebo (p<0.0001) in wAIHA patients.
- Overall response rate (Hb ≥100 g/L + ≥20 g/L increase without rescue) was 70% vs 22% (p<0.0001).
- Rescue therapy use reduced to 16% (sovleplenib) vs 54% (placebo); RBC transfusions reduced to 11% vs 43%.
- Median time to response was 3.1 weeks for sovleplenib vs 6.3 weeks for placebo.
- FDA-like NDA for wAIHA accepted and granted priority review by NMPA in April 2026; Breakthrough Therapy Designation granted March 2026.
- Resubmitted NDA for ITP accepted and granted priority review by NMPA in February 2026.
- Favorable safety profile: Grade ≥3 TEAEs in 43% (sovleplenib) vs 59% (placebo); no TEAE-related deaths or discontinuations in sovleplenib arm.
- HUTCHMED retains all worldwide rights to sovleplenib.
Financial Impact
Sovleplenib targets two sizable markets: wAIHA (significant unmet need in China with no approved targeted therapy) and ITP (430K existing patients, 41K new/year in China). Regulatory approval in either indication could generate substantial revenue; no financial projections provided.
Risk Factors
- Regulatory risk: NMPA may still reject or request additional data before approval.
- Commercial risk: WAIHA and ITP markets require physician education and pricing/reimbursement negotiations.
- Competition: Existing therapies (steroids, TPO-RAs, rituximab) remain available; sovleplenib must demonstrate clear cost-benefit advantage.
- China regulatory environment: drug pricing control and reimbursement policy could limit peak revenue.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3310859 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 12, 2026
1d ago
|
6-K
| $10.75 awaiting T+20 | awaiting T+20 | — | $10.96 (+1.95%) |
|
Jun 12, 2026
1d ago
|
Press Release
| $10.75 awaiting T+20 | awaiting T+20 | — | $10.96 (+1.95%) |
|
Apr 9, 2026
9w ago
|
Press Release
| $15.16 $13.43 | ▼ −11.41% | ▼ −18.98% | $10.96 (−27.70%) |
|
Mar 23, 2026
11w ago
|
Press Release
| $14.00 $14.87 | ▲ +6.21% | ▼ −1.21% | $10.96 (−21.71%) |
|
Mar 5, 2026
14w ago
|
Press Release
| $13.85 $15.42 | ▲ +11.34% | ▲ +15.12% | $10.96 (−20.87%) |
|
Mar 4, 2026
14w ago
|
Press Release
| $13.65 $15.14 | ▲ +10.96% | ▲ +15.37% | $10.96 (−19.68%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access